Abstract
Whereas clinically apparent atopic dermatitis (AD) can be confirmed by validated diagnostic criteria, the preclinical phenotype of infants who eventually develop AD is less well-characterized. Analogous to unaffected or nonlesional skin in established AD, clinically normal-appearing skin in infants who will develop clinical AD has distinct changes. Prospective studies have revealed insights into this preclinical AD phenotype. In this study, we review the structural, immunologic, and microbiome nature of the preclinical AD phenotype. Determination of markers that predict the development of AD will facilitate targeting of interventions to prevent the development or reduce the severity of AD in infants.
Original language | English |
---|---|
Pages (from-to) | 1001-1009 |
Number of pages | 9 |
Journal | Journal of Investigative Dermatology |
Volume | 144 |
Issue number | 5 |
Early online date | 2024 |
DOIs | |
Publication status | E-pub ahead of print - 2024 |
Keywords
- Atopic dermatitis
- Biomarkers
- Epidermal barrier
- Infants
- Personalized medicine